Trade Names: | |
Synonyms: | |
Status: | Approved (1979) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | C07AA12 |
UNII: | FEN504330V |
InChI Key | VWPOSFSPZNDTMJ-UCWKZMIHSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C17H27NO4 |
Molecular Weight | 309.41 |
AlogP | 0.63 |
Hydrogen Bond Acceptor | 5.0 |
Hydrogen Bond Donor | 4.0 |
Number of Rotational Bond | 5.0 |
Polar Surface Area | 81.95 |
Molecular species | BASE |
Aromatic Rings | 1.0 |
Heavy Atoms | 22.0 |
Action | Mechanism of Action | Reference |
---|---|---|
ANTAGONIST | Beta-1 adrenergic receptor antagonist | DailyMed |
Primary Target | |
---|---|
β1-adrenoceptor | |
β2-adrenoceptor |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Cytochrome P450
Cytochrome P450 family 19
Cytochrome P450 family 19A
Cytochrome P450 19A1
|
- | - | - | - | 0-0 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 76 |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Hemangioma | 3 | D006391 | ClinicalTrials |
Smoking Cessation | 2 | D016540 | ClinicalTrials |
Asthma | 2 | D001249 | ClinicalTrials |
Side effects | Relative Frequency (%) | Labels | |
---|---|---|---|
Cardiac disorders Bradycardia | 3.0 | ||
Cardiac disorders Dizziness | 3.0 | ||
General disorders and administration site conditions Asthenia | 2.0 | ||
General disorders and administration site conditions Fatigue | 2.0 | ||
General disorders and administration site conditions Feeling cold | 1.0 | ||
Vascular disorders Hypotension | 1.0 |
Resources | Reference |
---|---|
CAS NUMBER | 42200-33-9 |
ChEMBL | CHEMBL649 |
DrugBank | DB01203 |
EPA CompTox | DTXSID3023342 |
FDA SRS | FEN504330V |
Human Metabolome Database | HMDB0015334 |
Guide to Pharmacology | 554 |
KEGG | D00432 |
PharmGKB | PA450573 |
PubChem | 39147 |
SureChEMBL | SCHEMBL4177 |
ZINC | ZINC03831165 |